Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:15 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overweight Subjects Clear all
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

NCT02568306
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0165-1562, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 2 Interventional Results available

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

NCT06621017
View directory record Official record
Conditions
Obesity; Overweight
Interventions
ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg
Drug
Lead sponsor
Rose Pharma Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 4 Interventional Results available

A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

NCT05215418
View directory record Official record
Conditions
Blood Pressure
Interventions
VI-0521, Phentermine, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Anniston, Alabama • Mobile, Alabama • Lincoln, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Nov 3, 2026, 9:15 PM EST
Recruiting Phase 2 Interventional

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

NCT07282743
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 3, 2026, 9:15 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Epigenetic Effects of a Single Bout of Exercise on Cardiovascular Risk Factors and the Metabolome

NCT05034380
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Cardiovascular Diseases, Acute Exercise
Interventions
Acute exercise
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 3, 2026, 9:15 PM EST
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

NCT05653258
View directory record Official record
Conditions
Obesity, Healthy Lifestyle
Interventions
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy
Other · Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 3, 2026, 9:15 PM EST
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Nov 3, 2026, 9:15 PM EST
Completed Early Phase 1 Interventional Results available

Role of Methane in Glycemic Control

NCT01638429
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Neomycin, Rifaximin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639
View directory record Official record
Conditions
Obesity
Interventions
NO-13065, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 3 Interventional

Weight Loss and Exercise in Physically Limited Obese Elderly Subjects

NCT00146133
View directory record Official record
Conditions
Obesity, Frailty, Elderly
Interventions
diet, exercise
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Nov 3, 2026, 9:15 PM EST
Terminated Phase 3 Interventional

A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients

NCT00483171
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598, Non-pharmacological weight loss program (NPP), Low Calorie Diet
Drug · Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

NCT03308721
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-1177 A 1.0 mg/mL, PLACEBO
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety

NCT00645216
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873
View directory record Official record
Conditions
Obesity
Interventions
ERX1000, Placebo
Drug
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 2 Interventional Results available

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

NCT02311673
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 2 Interventional Results available

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

NCT03376802
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 2 Interventional

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

NCT04167553
View directory record Official record
Conditions
Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions
HM15136, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Nov 3, 2026, 9:15 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voriconazole in Obese Subjects

NCT01030653
View directory record Official record
Conditions
Healthy
Interventions
Voriconazole low dose, Voriconazole high dose
Drug
Lead sponsor
Manjunath Prakash Pai
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 3, 2026, 9:15 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

NCT04994769
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Epitomee Capsule
Device
Lead sponsor
Epitomee medical
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Nov 3, 2026, 9:15 PM EST